HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jon L Collins Selected Research

GW 3965

11/2009Liver X receptor agonist GW3965 dose-dependently regulates lps-mediated liver injury and modulates posttranscriptional TNF-alpha production and p38 mitogen-activated protein kinase activation in liver macrophages.
9/2008Liver X receptor agonists increase airway reactivity in a model of asthma via increasing airway smooth muscle growth.
6/2008ApoE promotes the proteolytic degradation of Abeta.
2/2006Activation of the liver X receptor protects against hepatic injury in endotoxemia by suppressing Kupffer cell activation.
4/2003Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue.
2/2003Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jon L Collins Research Topics

Disease

7Inflammation (Inflammations)
01/2017 - 02/2003
3Atherosclerosis
08/2007 - 05/2002
2Type 2 Diabetes Mellitus (MODY)
01/2017 - 06/2013
2Endotoxemia
11/2009 - 02/2006
2Cardiovascular Diseases (Cardiovascular Disease)
09/2004 - 05/2002
1Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2017
1Sepsis (Septicemia)
08/2011
1Peritonitis
08/2011
1Asthma (Bronchial Asthma)
09/2008
1Eosinophilia
09/2008
1Memory Disorders (Memory Loss)
06/2008
1Alzheimer Disease (Alzheimer's Disease)
06/2008
1Lung Diseases (Lung Disease)
11/2007
1Hypercholesterolemia
08/2007
1Necrosis
02/2006
1Tuberculosis (Tuberculoses)
05/2005
1Neurodegenerative Diseases (Neurodegenerative Disease)
09/2004
1Obesity
04/2003
1Insulin Resistance
04/2003
1Dermatitis
02/2003
1Allergic Contact Dermatitis
02/2003
1Irritant Dermatitis
02/2003
1Cerebrotendinous Xanthomatosis
01/2003
1Central Nervous System Diseases (CNS Diseases)
06/2002
1Niemann-Pick Diseases (Niemann Pick Disease)
06/2002
1Hypertriglyceridemia
05/2002

Drug/Important Bio-Agent (IBA)

6GW 3965IBA
11/2009 - 02/2003
6LigandsIBA
09/2008 - 05/2002
5Liver X ReceptorsIBA
08/2011 - 02/2003
4CholesterolIBA
01/2008 - 06/2002
3Glucose (Dextrose)FDA LinkGeneric
01/2017 - 04/2003
2LipidsIBA
01/2017 - 06/2013
2Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA
08/2011 - 09/2008
2BilirubinIBA
11/2009 - 02/2006
2Alanine Transaminase (SGPT)IBA
11/2009 - 02/2006
2CytokinesIBA
11/2009 - 02/2003
2Peptidoglycan (Murein)IBA
11/2009 - 02/2006
2Pharmaceutical PreparationsIBA
08/2007 - 09/2004
1Nonesterified Fatty Acids (NEFA)IBA
01/2017
1AcidsIBA
01/2017
1sodium-bile acid cotransporterIBA
06/2013
13- ((((3R,5R)- 3- butyl- 3- ethyl- 7- (methyloxy)- 1,1- dioxido- 5- phenyl- 2,3,4,5- tetrahydro- 1,4- benzothiazepin- 8- yl)methyl)amino)pentanedioic acidIBA
06/2013
1salicylhydroxamic acid (SHAM)IBA
08/2011
1Transcription Factors (Transcription Factor)IBA
08/2011
1Dinoprostone (PGE2)FDA Link
11/2009
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2009
1Biomarkers (Surrogate Marker)IBA
09/2008
1ApolipoproteinsIBA
06/2008
1Apolipoproteins E (ApoE)IBA
08/2007
1Triglycerides (Triacylglycerol)IBA
10/2005
1Anti-Bacterial Agents (Antibiotics)IBA
05/2005
1MacrolidesIBA
05/2005
1Rifampin (Rifampicin)FDA LinkGeneric
05/2005
1OxazoloneIBA
02/2003
1Irritants (Vesicants)IBA
02/2003
1SterolsIBA
02/2003
1OxysterolsIBA
02/2003
1phorbolIBA
02/2003
125-hydroxycholesterolIBA
02/2003
1Cytochrome P-450 CYP3AIBA
01/2003

Therapy/Procedure

1Punctures
08/2011
1Ligation
08/2011